gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Cytochrome P450, family 3, subfamily A, polypeptide 7

CYP3A7
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This enzyme hydroxylates testosterone and dehydroepiandrosterone 3-sulphate, which is involved in the formation of estriol during pregnancy. The enzyme also metabolizes some drugs such as aflatoxin B1. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. Transcript variants have been described, but it is not known whether these transcripts are normally produced. This gene undergoes readthrough transcription with the downstream CYP3AP1 pseudogene, resulting in an isoform with a novel C-terminus, as represented in GeneID:100861540. [provided by RefSeq, Feb 2012] (from NCBI)
Top mentioned proteins: CYP3A4, Cyp, CYP1A1, HAD, CAN
Papers on CYP3A7
Dynamics of Cytosine Methylation in the Proximal Promoters of CYP3A4 and CYP3A7 in Pediatric and Prenatal Liver.
New
Leeder et al., In Drug Metab Dispos, Feb 2016
UNASSIGNED: Members of the human CYP3A family of metabolizing enzymes exhibit developmental changes in expression whereby CYP3A7 is expressed in fetal tissues followed by a transition to expression of CYP3A4 in the first months of life.
Gene expression and pathway analysis of human hepatocellular carcinoma cells treated with cadmium.
New
Costa et al., New York City, United States. In Toxicol Appl Pharmacol, Dec 2015
Downregulated genes included the monooxygenase CYP3A7, involved in drug and lipid metabolism.
Expression of CYP3A4 and CYP3A7 in Human Foetal Tissues and its Correlation with Nuclear Receptors.
New
Ekström et al., Huddinge, Sweden. In Basic Clin Pharmacol Toxicol, Oct 2015
The aim of this study was to investigate the gene expression of CYP3A4 and the foetal CYP3A7 in human foetal tissues and their relation to gene expression and genetic variations in the nuclear receptors VDR, PPARα, PXR and CAR.
Histopathology of melanosis coli and determination of its associated genes by comparative analysis of expression microarrays.
New
Li et al., Chengdu, China. In Mol Med Report, Oct 2015
Expression microarray analysis revealed that the significantly downregulated genes were CYP3A4, CYP3A7, UGT2B11 and UGT2B15 in melanosis coli.
Variability in Expression of CYP3A5 in Human Fetal Liver.
New
Leeder et al., Seattle, United States. In Drug Metab Dispos, Aug 2015
Members of the cytochrome P450 3A (CYP3A) subfamily of drug metabolizing enzymes exhibit developmental changes in expression in human liver characterized by a transition between CYP3A7 and CYP3A4 over the first few years of life.
Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
New
Takahashi et al., San Francisco, United States. In Drug Metab Dispos, Jun 2015
In addition, the effect of CYP3A4 inhibition and induction on cobimetinib exposures was tested in the Cyp3a(-/-)Tg-3A4Hep/Int and PXR-CAR-CYP3A4/CYP3A7 mouse models, respectively.
CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.
New
Ahmed et al., Kansas City, United States. In Int J Exp Pathol, Apr 2015
Tissue microarrays slides were processed for immunohistochemical labelling for CYP3A4, CYP3A5 and CYP3A7 using liver sections as positive control.
Investigation of ligand selectivity in CYP3A7 by molecular dynamics simulations.
Zhang et al., Changchun, China. In J Biomol Struct Dyn, 2014
To compare the metabolic capabilities of CYP3A7-ligands complexes, three endogenous ligands were selected, namely dehydroepiandrosterone (DHEA), estrone, and estradiol.
Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation.
Taguchi et al., Toyama, Japan. In Biol Pharm Bull, 2014
The aim of this study was to characterize the kinetics of metabolite formation of the phosphodiesterase type-5 (PDE5) inhibitors sildenafil and tadalafil by CYP3A4, CYP3A5, and CYP3A7 isoforms.
Melatonin Interaction Resulting in Severe Sedation.
Vohra et al., Ottawa, Canada. In J Pharm Pharm Sci, 2014
In vitro analysis involving several melatonin products showed product-dependent inhibition of CYP1A2, CYP2C19 and CYP3A7.
A review of the role of genetic testing in pain medicine.
Review
Faynboym et al., Indianapolis, United States. In Pain Physician, 2014
METHODS: This article discusses the specific pain implications of genetic variations in CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A7, OPRM1, OPRK1, OPRD1, COMT, GABA, UGT, MC1R, GCH1, ABCB1, P-glycoprotein, 5HTR1A, 5HTR2A, MTHFR, CACNA2D2, and 5-HTTLPR.
Steroid profiling in pregnancy: a focus on the human fetus.
Review
Pařízek et al., Praha, Czech Republic. In J Steroid Biochem Mol Biol, 2014
Rising activities of placental CYP19A1 and oxidative isoforms of HSD17B, and of fetal CYP3A7 with advancing gestation may protect the fetus from hyperestrogenization.
From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation.
Review
Kuypers et al., Leuven, Belgium. In Int J Pharm, 2013
Commonly occurring polymorphisms in genes responsible for CNI metabolism (CYP3A4, CYP3A5, CYP3A7, PXR, POR, ABCB1 (P-gp) and possibly UGT) are able to explain an important part of interindividual variability.
Bioluminescent assays for ADME evaluation: dialing in CYP selectivity with luminogenic substrates.
Review
Klaubert et al., Madison, United States. In Expert Opin Drug Metab Toxicol, 2012
EXPERT OPINION: Highly selective luminogenic substrates for CYP1A1, CYP1A2, CYP2C9, CYP3A4, CYP3A7, CYP4A and CYP4F have been developed with utility for interrogating the roles of these enzymes in biochemical and cell-based formats.
Expression and regulation of human fetal-specific CYP3A7 in mice.
GeneRIF
Gonzalez et al., Bethesda, United States. In Endocrinology, 2012
Expression and regulation of human fetal-specific CYP3A7 in mice
CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility.
GeneRIF
Aschim et al., Oslo, Norway. In Int J Androl, 2011
There were no statistically significant differences in the distribution of CYP3A7 polymorphic alleles between testicular cancer cases and controls suggesting no contribution to individual susceptibility to testicular cancer.
Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7.
GeneRIF
Bureik et al., Saarbrücken, Germany. In Biochim Biophys Acta, 2011
Data show that both isoforms of CYP3A7 did not metabolize the anti-cancer drug sorafenib, and suggest that CYP3A7 activity does not influence the effectiveness of this anti-cancer drug against HCC.
Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin.
GeneRIF
Miller et al., Little Rock, United States. In Drug Metab Lett, 2010
Recombinant CYP3A4, CYP3A5 and CYP3A7 metabolized R- and S-warfarin to 10- and 4'-hydroxywarfarin with efficiencies that depended on the individual enzymes.
Cytochrome P450 3As gene expression and testosterone 6 beta-hydroxylase activity in human fetal membranes and placenta at full term.
GeneRIF
Ohmori et al., Matsumoto, Japan. In Biol Pharm Bull, 2009
The expression level of CYP3A7 messenger RNA is highest in chorion/decidua at a level which is about 3-fold of placenta and amnion, with the metabolic function to protect the fetus from exposure to drugs.
Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children.
Review
Yokoi, Kanazawa, Japan. In J Toxicol Sci, 2008
The CYP3A7 activity is relatively high just after birth, which affects the clearance of its substrate drugs.
share on facebooktweetadd +1mail to friends